Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | JSPR |
---|---|---|
09:32 ET | 204 | 18.79 |
09:41 ET | 6515 | 18.7248 |
09:45 ET | 100 | 18.76 |
09:52 ET | 1651 | 18.7 |
09:54 ET | 917 | 18.755 |
10:17 ET | 300 | 18.85 |
10:30 ET | 100 | 18.875 |
10:37 ET | 525 | 18.9 |
10:42 ET | 100 | 18.985 |
10:44 ET | 696 | 19 |
10:50 ET | 100 | 18.85 |
10:53 ET | 100 | 18.76 |
11:27 ET | 4229 | 18.805 |
11:36 ET | 100 | 18.56 |
11:40 ET | 100 | 18.56 |
11:44 ET | 458 | 18.5 |
11:45 ET | 100 | 18.5 |
11:47 ET | 100 | 18.31 |
11:54 ET | 100 | 18.21 |
11:56 ET | 200 | 18.16 |
11:58 ET | 100 | 18.18 |
12:00 ET | 100 | 18.2 |
12:02 ET | 200 | 18.23 |
12:03 ET | 100 | 18.21 |
12:14 ET | 100 | 18.385 |
12:16 ET | 300 | 18.405 |
12:18 ET | 400 | 18.57 |
12:20 ET | 260 | 18.48 |
12:21 ET | 260 | 18.73 |
12:30 ET | 100 | 18.51 |
12:39 ET | 500 | 18.7009 |
12:41 ET | 100 | 18.625 |
12:43 ET | 300 | 18.705 |
12:56 ET | 100 | 18.58 |
12:59 ET | 100 | 18.36 |
01:01 ET | 100 | 18.35 |
01:06 ET | 100 | 18.25 |
01:08 ET | 100 | 18.24 |
01:12 ET | 100 | 18.24 |
01:14 ET | 100 | 18.23 |
01:17 ET | 100 | 18.38 |
01:19 ET | 200 | 18.38 |
01:26 ET | 100 | 18.5 |
01:28 ET | 300 | 18.425 |
01:48 ET | 100 | 18.43 |
02:00 ET | 200 | 18.39 |
02:06 ET | 200 | 18.44 |
02:11 ET | 300 | 18.385 |
02:56 ET | 100 | 18.465 |
03:03 ET | 596 | 18.38 |
03:41 ET | 400 | 18.37 |
03:45 ET | 300 | 18.25 |
03:48 ET | 200 | 18.26 |
03:50 ET | 400 | 18.24 |
03:52 ET | 300 | 18.36 |
03:54 ET | 500 | 18.15 |
03:56 ET | 400 | 18.145 |
03:57 ET | 500 | 18.2 |
03:59 ET | 6293 | 18.16 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Jasper Therapeutics Inc | 284.3M | -3.6x | --- |
Precigen Inc | 339.8M | -2.1x | --- |
scPharmaceuticals Inc | 269.7M | -3.3x | --- |
Telomir Pharmaceuticals Inc | 161.1M | -8.3x | --- |
ASP Isotopes Inc | 157.4M | -4.5x | --- |
Global Pharmatech Inc | 138.3M | -3.6x | --- |
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $284.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 15.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.22 |
EPS | $-5.10 |
Book Value | $7.03 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.